SCHEMBL1839652

SCHEMBL1839652

COC(=O)N1CCC2(CCN(c3ccnc4[nH]cc(-c5ccnc(N)n5)c34)C2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 6/20 0.48
CDK9 P50750 6/20 0.48
CDK5 Q00535 6/20 0.48
CDK5R1 Q15078 6/20 0.48
CCNA2 P20248 5/20 0.48
CDK2 P24941 5/20 0.48
CCNA1 P78396 5/20 0.48
ROCK1 Q13464 10/20 0.47
CDC42BPB Q9Y5S2 10/20 0.47
ROCK2 O75116 5/20 0.46
HSD17B10 Q99714 3/20 0.44
TSHR P16473 2/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C9 P11712 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
CYP3A4 P08684 2/20 0.43
CDC42BPA Q5VT25 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2244887 0.90 ROCK1 (0.48) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1840503 0.82 ROCK1 (0.55) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1839432 0.81 ROCK1 (0.54) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1838633 0.80 ROCK1 (0.66) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1839600 0.79 CCNT1 (0.53) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1837753 0.78 CCNT1 (0.56) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1842027 0.77 CCNT1 (0.54) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1836783 0.77 CCNT1 (0.54) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL1841471 0.77 ROCK1 (0.49) CCNT1CDK9CDK5CDK5R1CCNA2
SCHEMBL27835146 0.77 ROCK1 (0.55) CCNT1CDK9CDK5CDK5R1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 CCNT1 25/4885CDK9 6/4885CDK5 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.